Zdrowie i gospodarka · 29/06/2018
FDA Requests Public Comment on Biosimilars User Fee Program Information Collection
The Food and Drug Administration is seeking public input on a proposed information collection related to its Biosimilars User Fee Program, which is required under the Paperwork Reduction Act of 1995.
Source: Federal Register — Food and Drug AdministrationOpen original release →